TABLE 1.
Comparison of clinicopathological features between HER2-zero and HER2-low HR-negative BC patients.
| Clinicopathological features | n | HER2-zero n (%) | HER2-low n (%) | χ2 | p |
|---|---|---|---|---|---|
| Age at diagnosis | 4.455 | 0.035 | |||
| <50 | 151 | 62 (55.4) | 89 (43.0) | ||
| ≥50 | 168 | 50 (44.6) | 118 (57.0) | ||
| Menopausal status at diagnosis | 0.537 | 0.464 | |||
| Premenopausal | 162 | 60 (53.6) | 102 (49.3) | ||
| Postmenopausal | 157 | 52 (46.4) | 105 (50.7) | ||
| Family history | 0.041 | 0.840 | |||
| No | 292 | 103 (92.0) | 189 (91.3) | ||
| Yes | 27 | 9 (8.0) | 18 (8.7) | ||
| Clinical T stage | 0.975 | 0.614 | |||
| cT0-1 | 66 | 23 (20.5) | 42 (20.3) | ||
| cT2 | 158 | 59 (52.7) | 99 (47.8) | ||
| cT3-4 | 95 | 30 (26.8) | 66 (31.9) | ||
| Clinical N stage | 13.194 | 0.001 | |||
| cN0 | 110 | 53 (47.3) | 57 (27.5) | ||
| cN1 | 167 | 45 (40.2) | 122 (58.9) | ||
| cN2-3 | 42 | 14 (12.5) | 28 (13.5) | ||
| Pathological pattern | 1.523 | 0.217 | |||
| Invasive ductal carcinoma | 293 | 103 (92.0) | 181 (87.4) | ||
| Other | 9 | 9 (8.0) | 26 (12.6) | ||
| Histological grading | 55.196 | <0.001 | |||
| Ⅰ-Ⅱ | 166 | 27 (24.1) | 139 (67.1) | ||
| Ⅲ | 153 | 85 (75.9) | 68 (32.9) | ||
| Lymphovascular Invasion | 0.528 | 0.467 | |||
| No | 252 | 91 (81.3) | 161 (77.8) | ||
| Yes | 67 | 21 (18.7) | 46 (22.2) | ||
| TIL (%) | 0.239 | 0.625 | |||
| <10 | 278 | 99 (88.4) | 179 (86.5) | ||
| ≥10 | 41 | 13 (11.6) | 28 (13.5) | ||
| Ki67(%) | 6.242 | 0.012 | |||
| ≤14 | 64 | 31 (27.7) | 33 (15.9) | ||
| >14 | 255 | 81 (72.3) | 174 (84.1) | ||
| p53 (%) | 0.643 | 0.423 | |||
| ≤10 | 102 | 39 (34.8) | 63 (30.4) | ||
| >10 | 217 | 73 (65.2) | 144 (69.6) | ||
| CK5/6 | 0.215 | 0.643 | |||
| Negative | 134 | 49 (43.8) | 85 (41.1) | ||
| Positive | 185 | 63 (56.2) | 122 (58.9) | ||
| EGFR | 0.084 | 0.772 | |||
| Negative | 88 | 32 (28.6) | 56 (27.1) | ||
| Positive | 231 | 80 (71.4) | 151 (72.9) |